12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Letairis ambrisentan: Phase IV start

Next year, Gilead will start the double-blind, international Phase IV AMBITION trial to compare ambrisentan and tadalafil both alone and in combination as first-line therapy in over 300 patients. GlaxoSmithKline has ex-U.S. commercialization rights to...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >